Our lead program VENT-02, a brain-penetrant NLRP3 inhibitor, is in a Phase 2a trial for Parkinson’s disease. Our second lead program – VENT-03, a first-in-class cGAS inhibitor – is expected to enter Phase 2 development for lupus in 2025.
We are a clinical-stage biopharmaceutical company leveraging our machine learning-enabled ReSOLVE™ platform to advance a pipeline of novel medicines in immunology, inflammation, and neurology.